

Registered number: 02165552

Charity number: 519357

**NORTH WEST CANCER RESEARCH (INCORPORATING CLATTERBRIDGE
CANCER RESEARCH "CCR")**

TRUSTEES' REPORT AND FINANCIAL STATEMENTS

FOR THE YEAR ENDED 30 SEPTEMBER 2020

**NORTH WEST CANCER RESEARCH (INCORPORATING CLATTERBRIDGE CANCER
RESEARCH “CCR”)**

(A company limited by guarantee)

CONTENTS

	Page
Reference and administrative details of the charity, its trustees and advisers	3 - 4
Chairman’s Statement	5 – 6
Trustees’ Report	7 – 18
Independent Auditor’s Report	19 – 22
Consolidated Statement of Financial Activities	23
Consolidated Balance Sheet	24
Charity Balance Sheet	25
Consolidated Cash Flow Statement	26
Notes to the Financial Statements	27 - 47

NORTH WEST CANCER RESEARCH (INCORPORATING CLATTERBRIDGE CANCER RESEARCH “CCR”)

(A company limited by guarantee)

REFERENCE AND ADMINISTRATIVE DETAILS OF THE COMPANY, ITS TRUSTEES AND ADVISERS FOR THE YEAR ENDED 30 SEPTEMBER 2020

Trustees and officers of the Board

Mr N S Lanceley FCA, DL	Chairman and Chair of the Nominations Committee
Mrs F Street	Vice Chair
Mrs H Atherton	Chair of the Marketing and Fundraising Committee
Mrs C Bond CPFA	Honorary Treasurer
Mr M Haig	
Miss C Jones BA, ACIS	Chair of the Investment Committee
Mrs M Owen	Resigned 15 October 2019
Dr P Robertshaw PhD, Dip DM	
Prof D R Sibson PhD, BSc	Resigned 25 March 2020
Mr Stephen Claus LLB	
Mr P Webster	Appointed 10 February 2020
Mr M Ore	Appointed 10 February 2020
Dr S Kothari	Appointed 10 February 2020
Mr M Carter	Appointed 10 February 2020

Patrons

The Most Reverend John Davies	The Archbishop of Wales
The Most Reverend Malcolm McMahon	The Archbishop of Liverpool
The Right Reverend Mark Tanner	The Lord Bishop of Chester
The Right Reverend Paul Bayes	The Bishop of Liverpool
The Right Reverend Gregory Cameron	The Bishop of St Asaph
The Right Reverend Peter Eagles	The Bishop of Sodor and Man
The Right Reverend Beverley Mason	The Bishop of Warrington
Edmond Seymour Bailey	Lord Lieutenant of Gwynedd
Mrs Tia Jones	Lord Lieutenant of Powys
Mark Blundell	Lord Lieutenant of Merseyside
Prof Dame Janet Beer	The Vice Chancellor, The University of Liverpool
Prof Ian Campbell	The Vice Chancellor, Liverpool John Moores University
Dr Steve Ryan	The President of the Liverpool Medical Institution
The Most Honourable Charles Paget	The Marquess of Anglesey
The Most Honourable David Cholmondeley	The Marquess of Cholmondeley
Lord Mostyn	
Dame Lorna Muirhead	
Henry Bowring	
Michael Potts	

**NORTH WEST CANCER RESEARCH (INCORPORATING CLATTERBRIDGE CANCER
RESEARCH “CCR”)**

(A company limited by guarantee)

**REFERENCE AND ADMINISTRATIVE DETAILS OF THE COMPANY, ITS TRUSTEES AND
ADVISERS FOR THE YEAR ENDED 30 SEPTEMBER 2020 (continued)**

Registered office

North West Cancer Research
200 London Road
Liverpool
L3 9TA

Bankers

Natwest
247 High Street
Bangor
Gwynedd, LL57 1RW

Solicitors

Brabners LLP
Horton House
Exchange Flags
Liverpool, L3 9QJ

Investment Managers

Investec Wealth and Investment Ltd
The Plaza
Old Hall Street
Liverpool, L3 9AB

Auditors

Crowe U.K. LLP
The Lexicon
Mount Street
Manchester, M2 5NT

Senior Management Team

Alastair Richards
Alex Preston
Cara Newton

Chief Executive Officer (and Company Secretary)
Head of Finance and Administration
Head of Fundraising & Marketing

NORTH WEST CANCER RESEARCH (INCORPORATING CLATTERBRIDGE CANCER RESEARCH “CCR”)

(A company limited by guarantee)

CHAIRMAN’S STATEMENT FOR THE YEAR ENDED 30 SEPTEMBER 2020

The Chairman presents his statement for the period.

The financial year ending 30 September 2020 has been one of change and challenge for North West Cancer Research (“NWCR”) as we, our region and the rest of the country have got to grips with the Covid-19 pandemic and the effect that it has had on healthcare and society. Many of our plans for the year were thwarted and much of what we had hoped to work on was cancelled because of the pandemic. However, our work in funding excellent research into cancer has continued and we are delighted that we have been able to fund new projects in new areas of work during the year.

It is worthwhile at this point to cover some of the impacts which covid-19 has had on NWCR since March. Even before lockdown had been considered in the UK, we were starting to feel some of the effects of the pandemic as world stock-markets reacted to the disruption to supply chains and the virus in China. Between 1 January and 31 March 2020 our investments fell by 21% or around £2.1m as the effects became clear. Clearly from March onwards all fundraising and outreach activities, along with research taking place in partner laboratories was frozen. However, we were able to continue our funding rounds – selecting the very best new projects – but with a reduced level of funding. Where possible, we have made use of the government’s Coronavirus Job Retention Scheme and a number of the staff team have been furloughed for much of the year. We have also sought to minimise our costs wherever possible.

Our financial results for the year reflect a deficit, but a situation which could have been so much worse if it were not for the efforts of our supporters, our staff team and our investment managers. Our supporters have not been able to run the events and activities that they normally would but they have come to the fore and have provided us with donations which have enabled us to keep moving forwards. Our staff team have innovated and found new ways of working which we previously didn’t think were possible and have been creative in finding new ways to reach people. Finally, the way in which our investments were managed and diversified means that we were able to recover lost value quickly.

We are delighted that during this year we have been able to continue funding excellent new research projects and that competition for funding remains intense. Projects have included those studying the early diagnosis and effective treatment of lung, prostate and head and neck cancers – all cancer types which are common in our region. We look forward to seeing the advances these provide.

I would like to thank my Board of Trustees who continue to provide excellent service working to move NWCR forwards. They give their time freely and provide excellent advice to myself and to the Charity’s management team. Note should be made of Professor Ross Sibson who stepped down as a Trustee in March 2020 following many years of excellent service to both NWCR and prior to that to CCR. Ross’s knowledge as a researcher and scientist have been invaluable to us and he has frequently been a voice of

**NORTH WEST CANCER RESEARCH (INCORPORATING CLATTERBRIDGE CANCER
RESEARCH “CCR”)**

(A company limited by guarantee)

**CHAIRMAN’S STATEMENT
FOR THE YEAR ENDED 30 SEPTEMBER 2020 (continued)**

calm authority and assurance on the Board.

During 2020 we have also welcomed four new Trustees to the Board and I look forward to working with them in the future. Although they joined in February, their introduction to the Charity has been different to what they might have expected although they are already bringing new skills and strengths to the Board.

I would also like to thank the staff team and all of those who have been involved with NWCR during 2019/20. As with many charities, we are reliant upon our donors and those who kindly leave us gifts in legacies. NWCR also has the benefit of having in place local branches who provide excellent support and continue to develop their presence in towns across our area. There has also been excellent support by Patrons, Ambassadors and many volunteers. We also note the growing support which we receive from corporate funders.

Looking forward NWCR, like many charities, faces challenges and uncertainties. However, I and my Trustees believe that during 2019/20 we have continued to build strong foundations which will help us to be both more resilient and more dynamic in the future. Together we aim to fight cancer and in particular the cancers which have the greatest impact on our region. To this end, we are making progress and this will continue in the coming years.



Name Mr N S Lanceley
Chairman

Date 25 January 2021

NORTH WEST CANCER RESEARCH (INCORPORATING CLATTERBRIDGE CANCER RESEARCH “CCR”)

(A company limited by guarantee)

TRUSTEES’ REPORT FOR THE YEAR ENDED 30 SEPTEMBER 2020

The Trustees (who are also directors of the Charity for the purposes of the Companies Act) present their Annual Report, together with the audited Financial Statements of North West Cancer Research (incorporating Clatterbridge Cancer Research “CCR”) (the Company) for the year ended 30 September 2020. The Trustees confirm that the Financial Statements comply with the Charities Act 2011, the Companies Act 2006, the Memorandum and Articles of Association, and Accounting and Reporting by Charities: Statement of Recommended Practice applicable to charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102) (effective 1 January 2015).

Since the Company qualifies as small under section 383, the Strategic Report required of medium and large companies under The Companies Act 2006 (Strategic Report and Director’s Report) Regulations 2013 is not required.

STRUCTURE, GOVERNANCE AND MANAGEMENT

The Company is registered as a charitable company limited by guarantee and was set up by a Memorandum of Association on 24 September 1998 and revised on 1 October 2009, 4 October 2012 and 22 March 2018. The Company’s registered charity number is 519357.

The Board of Trustees (“the Board”) is responsible for the overall governance of the Charity. The Trustees and members of the Board who have served during the period are set out on page 3.

Trustees are normally co-opted onto the Board and their appointment confirmed at the following Annual General Meeting. Appointment is normally for a period of three years, although this can be renewed through re-election by the members to create a maximum term in office of 9 years. Trustees are appointed to the Board through two routes, with the oversight of any appointment being undertaken by the Nominations Committee (see below). The majority of appointments are made through acknowledging a skills gap amongst the current Trustees and advertising any vacancy. However, the Board does recognise that there are individuals with exceptional skills or connections which it may be useful to have on the Board and so the option remains to directly approach potential Trustees. During late-2019 we advertised for new Trustees in a range of different areas of expertise and we are delighted that four new Trustees joined the Board in February 2020.

New Trustees are normally provided with an introduction into the nature and running of the Charity, including seeing funded researchers in action and, meeting the staff team and volunteer fundraising branches. They are also provided with a raft of information about the Charity in order to enable them to understand the organisation’s history and current position. Providing some of this induction has been a challenge in 2020 due to the pressures individuals face.

NORTH WEST CANCER RESEARCH (INCORPORATING CLATTERBRIDGE CANCER RESEARCH “CCR”)

(A company limited by guarantee)

TRUSTEES' REPORT FOR THE YEAR ENDED 30 SEPTEMBER 2020 (continued)

STRUCTURE, GOVERNANCE AND MANAGEMENT (continued)

Board meetings take place six times per year. It is the responsibility of the Board to develop organisational strategies in partnership with the management team and to review operational performance, to set budgets and to approve operational plans. The Board also sets the pay of staff, including the senior management team. This is done in comparison with market rates.

The Board delegates the exercise of certain powers as set out below. This is controlled through regular reporting back to the Board so that Trustees can oversee all decisions made under delegated powers. The Committees and individuals to which the delegation takes place are shown below:

a. Officers of the Board

There are three officers of the Board to whom responsibilities are delegated. These are the Chairman, the Vice-Chair and the Honorary Treasurer. The Chairman acts as a key external representative for the Charity, as well as being the main link from the Trustees to the Chief Executive Officer. The Chairman also ensures that decisions are lawful, constitutional and within the remit of the Charity. In their absence, the role is covered by the Vice-Chair. The Honorary Treasurer oversees the financial affairs of the organisation and takes the lead in providing financial reporting advice to the Board.

b. Marketing and Fundraising Committee

Working closely with the Head of Fundraising and Marketing and the Fundraising Team, the Committee provides advice and assurance to the Board. It also has key responsibilities in approving strategic and annual plans for marketing, communications and fundraising activities and for assessing the effectiveness of these.

c. Investment Committee

The Committee seeks to provide advice and assurance to the Board in overseeing the Charity's investments and the performance of those. This includes recommending to the Board the approval of the Charity's Statement of Investment Principles along with the appointment or re-appointment of investment and other related professional advisers.

d. Nominations Committee

The Nominations Committee oversees and recommends to the Board key appointments for the Charity. This includes members of the Board of Trustees, Officers of the Board and the appointment of the Chief Executive Officer. The Committee also oversees the membership of the Charity and, in addition, the appointment of Honorary Members and Patrons.

NORTH WEST CANCER RESEARCH (INCORPORATING CLATTERBRIDGE CANCER RESEARCH “CCR”)

(A company limited by guarantee)

TRUSTEES’ REPORT FOR THE YEAR ENDED 30 SEPTEMBER 2020 (continued)

STRUCTURE, GOVERNANCE AND MANAGEMENT (continued)

e. Chief Executive Officer

The Chief Executive Officer is responsible for day-to-day management of the Charity’s affairs and for implementing policies agreed by the Board. The Chief Executive is assisted by a team of senior managers and other staff.

In addition to the Committees and individuals above to whom responsibilities are directly delegated, note should also be made of the Groups which advise the Board on the quality of research to be funded. These are:

- **Research Strategy Group**
The Research Strategy Group advises the Board on its research strategy. This directs the Charity’s spending and shapes the areas and types of funding it will offer. The Group comprises scientists predominantly drawn from funded universities but who are independent of the programmes funded by the Charity.
- **Cancer Discovery Advisory Group**
The Cancer Discovery Advisory Group undertakes the scientific assessment of applications for early stage research funding looking at cell structures, DNA and proteomics.
- **Under-pinning Research Advisory Group**
The Under-pinning Research Advisory Group considers projects which seek to develop theoretical knowledge and start to identify how it can be applied to patients and techniques which will benefit the population.
- **Applied Research Advisory group**
The Applied Research Advisory Group reviews funding applications for projects which seek to improve the effectiveness and experience of current treatments being used in our area. This includes work in the area of psycho-social oncology.
- **Cancer inequalities Advisory Group**
The Cancer Inequalities Group scrutinises projects which study differences in how different parts of the diverse community in our area experience cancer, receive and respond to treatment.

The majority of the groups above were put in place during 2018/19 in order to provide for a variety of different funding rounds which supported different types of research – some of which were new to NWCR. After each of the groups has met and funded projects an assessment will be carried out of the nature of the work funded with consideration being given to the value of each of the process.

NORTH WEST CANCER RESEARCH (INCORPORATING CLATTERBRIDGE CANCER RESEARCH “CCR”)

(A company limited by guarantee)

TRUSTEES' REPORT FOR THE YEAR ENDED 30 SEPTEMBER 2020 (continued)

PUBLIC BENEFIT

The Trustees have given due consideration to the Charity Commission's guidance on public benefit as is required under the Charities Act 2011. The Report below provides detailed information on the activities undertaken by the Charity. All of the Charity's activities are directly in the public benefit and there are no financial benefits from the award of research funding.

The outcomes of the research are for the public benefit. The benefits are primarily for those who suffer from the types of cancer covered by our research. Society generally benefits as improved treatment reduces the numbers of, and stress from anxiety from, early deaths from cancer.

OBJECTIVES, ACTIVITIES AND ACHIEVEMENTS

a. Objectives

The object of the Company is to promote and carry out research into cancer, its diagnosis and its treatment, and to disseminate the results of such research to the public. It is the policy of North West Cancer Research to further its objects by financing research in the North West of England and North Wales into causes of all forms of cancers and the mechanisms by which cancers arise and exert their effects in the area. The Charity re-assessed its strategy in 2017 and decided to focus research spending on the following areas:

- Researching the impact of cancer;
- Researching the causes of cancer;
- Applied or clinical cancer research;
- Fundamental cancer research;
- Building the capacity for cancer research in our region; and
- Funding future cancer researchers.

Together these create a focus on research into the cause, care and cure of cancer. Our strategy was reviewed and reconsidered by the Board of Trustees in February 2020 and will be published at the end of the year. This will focus in on three areas as follows:

- Understanding our region;
- Undertaking research
- Education and awareness

NORTH WEST CANCER RESEARCH (INCORPORATING CLATTERBRIDGE CANCER RESEARCH “CCR”)

(A company limited by guarantee)

TRUSTEES' REPORT FOR THE YEAR ENDED 30 SEPTEMBER 2020 (continued)

ACTIVITIES AND ACHIEVEMENTS (continued)

b. Activities and achievements

The Charity furthers its objectives through funding research carried out in Higher Education Institutions and NHS Trusts within the area. At the present time funded research programmes are underway at the University of Liverpool, Bangor University, University of Chester and Lancaster University as well as at Blackpool Teaching Hospitals NHS Trust. Current funding programmes include:

- Funding for research projects which focus on the cause, care or cure for cancer, This might be for a particular type of treatment, in fundamental science, cancer cell biology, drug utilisation or medical practice;
- Funding for key posts within academic institutions which will build the capacity of research, along with funding PhD students;
- Funding for the incubation of new projects in order to aid the development of early stage hypotheses;

Currently, there are just over 50 active funding streams supporting projects, students, lecturers, fellows and other activities. During the year, five research project grants were awarded at a total cost of £1.16 million. In addition, the charity carried out activities which promote the benefits of research along with general scientific and cancer specific knowledge. Recently, there has been an increased focus on the impact of currently funded research and regular impact data is collected to measure the effectiveness of research and the importance of this for people in the region. The new impact report is due to be published in early 2021 and will highlight the success of a range of projects including new patents, leveraged funding and worldwide collaborations.

The Charity is a member of the Association of Medical Research Charities and ensures that it complies with their policies of peer review for research project funding. This means that any application will be subject to scrutiny by the appropriate group (see above) to ensure that it is research of the highest available standard and that award is made in an impartial manner.

Funding for research is generated through active fundraising, legacy receipts and investment returns. The Charity benefits from a network of branches or committees of volunteers who organise a wide variety of fundraising activities. These activities continue to generate a material income for the Charity which represents the hard work and dedication of its many supporters, to whom the Board express their sincere gratitude. Branches are spread across Cumbria and Lancashire to the north, Merseyside and Cheshire and also North and Mid Wales.

NORTH WEST CANCER RESEARCH (INCORPORATING CLATTERBRIDGE CANCER RESEARCH “CCR”)

(A company limited by guarantee)

TRUSTEES’ REPORT FOR THE YEAR ENDED 30 SEPTEMBER 2020 (continued)

ACTIVITIES AND ACHIEVEMENTS (continued)

The Charity is focussed upon consolidating and increasing its fundraised income and annually reviews the team along with the methods used to generate funds. An essential element of this is to draw income from a wider range of sources including corporates, community groups, trusts and individuals while keeping costs down – something which has been critical during 2019/20. During this financial year there was a decrease in fundraised income as it has not been possible to undertake many events and for our fundraising groups to operate as normal. The opportunity afforded by the Covid-19 pandemic was taken to review our approach to fundraising and to ensure that it is as lean as possible in the current uncertain climate.

RISK MANAGEMENT

The Trustees have assessed the major risks to which the Charity is exposed, in particular those related to the operations and finances of the Charity, and are satisfied that systems and procedures are in place to mitigate our exposure to the major risks. The risks to which the organisation is exposed are considered by the Board at each meeting, with a more in-depth review taking place twice a year. The risk profile will change over time as the organisation strengthens its controls and considers strategies to mitigate risks. The risks below are the ones of which the Board is particularly mindful:

- Investment risks – The organisation holds its reserves in investments which can be subject to fluctuations in value. The Charity is an investor for the long-term and, as such, it has benefited significantly from the increase in value of its holdings. However, it is aware of the need to maintain a balanced portfolio of risks and to spread the profile of its investments in order to protect itself from short-term fluctuations in the market;
- Reputational risks – The Charity sector has seen its reputation significantly impacted in recent years as a number of scandals have taken place. North West Cancer Research is very aware of the need to uphold the highest levels of governance and to consider carefully its actions when fundraising and promoting the organisation; and
- Information technology risks – The Charity is dependent upon a number of IT systems, support for which is provided by external bodies. Although the Trustees have ensured that a range of risk controls and security systems are in place, there remain risks around cyber-attacks and the loss of access to critical systems.

NORTH WEST CANCER RESEARCH (INCORPORATING CLATTERBRIDGE CANCER RESEARCH “CCR”)

(A company limited by guarantee)

TRUSTEES’ REPORT FOR THE YEAR ENDED 30 SEPTEMBER 2020 (continued)

RISK MANAGEMENT (continued)

Like many charities, NWCR is aware of the potential impacts which may result from the UK leaving membership of the European Union. Many talented researchers from across Europe and beyond currently work in academic institutions where the Charity funds work and at this point it is unclear as to what the potential impacts of this change are. The Trustees continue to monitor this situation in order to understand the results which may occur.

ACHIEVEMENTS AND PERFORMANCE

a. Going concern

Clearly the Covid-19 pandemic has had a significant impact on many charities including NWCR. During the year we have experienced significant fluctuations in value of our investments as well as a reduction in income as detailed below. However, after making appropriate enquiries, the Trustees have a reasonable expectation that the Company has adequate resources to continue in operational existence for the foreseeable future and there are no material uncertainties. For this reason, they continue to adopt the going concern basis in preparing the Financial Statements. All current commitments made to fund research work and posts have been provided for within the Balance Sheet. Further details regarding the adoption of the going concern basis can be found in the Accounting Policies within the Financial Statements.

b. Financial review of the year

During the year the headline income of the Charity was down on the previous year with total income of £1,541k against £1,800k in the previous year. The Charity has traditionally drawn its income from three sources – legacies, fundraising and investment returns and each of these needs to be considered separately when reviewing performance. The largest element in the year was income from legacies. These increased slightly on 2018/19 rising from £778k to £921k. Legacy income is always unpredictable but the Charity remains deeply grateful for those supporters who leave us gifts in their will. Income from fundraising activities and donations, including gifts in kind decreased during the year by £201k as a result of the Covid-19 pandemic and the cancellation of many planned activities for the spring and summer of 2020. The largest fall was in funds raised from events, which decreased by 69% or £71k against the previous year. Another large area of decrease was from our fundraising committees who had to cancel so many of their planned activities and who saw income fall by 47% or £70k. We are so grateful for the on-going support of our donors who have given generously to us during this year and who have helped to provide much needed funds. The figures for fundraising and donations also include the income received from the government’s Coronavirus Job Retention Scheme – which provided £51k of wage support during the year.

NORTH WEST CANCER RESEARCH (INCORPORATING CLATTERBRIDGE CANCER RESEARCH “CCR”)

(A company limited by guarantee)

TRUSTEES’ REPORT FOR THE YEAR ENDED 30 SEPTEMBER 2020 (continued)

Financial review of the year (continued)

Income from investments reduced from £411k to £211k as our investment aims were amended but also reflecting cash draw-downs from our portfolio in recent years.

During the year the Charity funded a number of new grant programmes, but worked with a significantly reduced number of funding rounds because of the uncertainty in the environment. Funding rounds which would have completed during the later months of the year, and the beginning of the following year (2020/21) were paused pending better information as to the financial impacts of the Covid-19 pandemic. In spite of this we were able to fund five new multi-year projects along with items of equipment and other items which in total cost £1,277k. Projects included those focussed on understanding the fundamental cell biology of cancer along with research into improved treatments and biomarkers to improve the early detection of cancer. The funded projects included work on prostate cancer, head and neck cancer and lung cancers – all forms of cancer which have a significant impact in our region.

Funding was also provided to support additional students studying a Masters of Research in cancer at Bangor University and working in collaboration with the Knowledge, Economy, Skills Scholarship (KESS2) programme. Funding for the completion of all projects is provided for, in full, at the time a commitment is made and is included in our balance sheet as a creditor.

At the end of the financial year, reserves had fallen from £4.3m to £3.4m as the Charity continues its programme to invest in cancer research work and intentionally draw down reserves but also as investment values had fallen. As is noted above, the Covid-19 pandemic resulted in a significant fall in investment values in the first quarter of 2020 but much of this loss of value had been recovered by the end of the financial year.

c. Fundraising

The Charity is registered with the Fundraising Regulator and with the Fundraising Preference Service. It employs a fundraising team which is overseen by an experienced fundraising manager who ensures that high standards are maintained at all times. The Charity does not employ commercial fundraisers. It does not exchange data with other parties and has not purchased supporter mailing lists.

NORTH WEST CANCER RESEARCH (INCORPORATING CLATTERBRIDGE CANCER RESEARCH “CCR”)

(A company limited by guarantee)

TRUSTEES’ REPORT FOR THE YEAR ENDED 30 SEPTEMBER 2020 (continued)

Fundraising (continued)

During the year there was one complaint (2018/19: two) made to the Charity by donors. This was resolved to the satisfaction of those involved and the Charity will continue to learn from the times when it doesn’t get things right the first time.

NWCR maintains records of all supporters, donors and gifts received and ensures that these records are regularly reviewed and monitored to check that contact with donors is done in an appropriate manner and in line with any preference which they have stated to us. Mailings to donors are limited in number and the Charity does not carry out active telephone fundraising campaigns. The Charity does not knowingly contact vulnerable individuals or those who have opted out of mailing contact.

d. Reporting and monitoring performance

The Board of Trustees set an annual budget against which performance is monitored on a monthly basis. Management of the budget is delegated (as noted above) but Trustees monitor performance against it. A set of performance indicators is now being developed in order to assist the Board in understanding management performance and to help in quantifying the impact of our research.

KEY POLICIES

The Board has a number of policies which are key in the operation of the Charity. These are:

a. Investment policy and performance

Except for the restrictions imposed by the ethical policy, the Charity places no further restrictions on the amount or type of investments made by the Charity and adheres to all relevant legislation. During the year the Charity’s investments were overseen by Investec Wealth and Investment Ltd who managed the portfolio on a discretionary basis, within agreed limits, monitored against an appropriate index, and reviewed on a regular basis by the Trustees. The main objective is to provide a balance between capital growth and income in order to meet the Company’s future commitments which, by their very nature, generally run for periods of 3 to 5 years ahead. The Charity’s Investment Strategy targeted an income from the Investment Managers during the year of £300,000 but this was not achieved as a result of the reductions in dividends which companies implemented as a result of the Covid-19 pandemic.

The Company has barred investment in tobacco businesses and will not make any new investments in companies which make a significant proportion of their profits from alcohol and sugar-related products. No social investment is currently undertaken.

NORTH WEST CANCER RESEARCH (INCORPORATING CLATTERBRIDGE CANCER RESEARCH “CCR”)

(A company limited by guarantee)

TRUSTEES' REPORT FOR THE YEAR ENDED 30 SEPTEMBER 2020 (continued)

b. Reserves policy

North West Cancer Research recognises research grants as they are made, and hence at the end of financial year 2019/20 it had provided for research costs which will be paid in future years of £6.6m (2018/19: £6.4m) which had been approved but not yet utilised. Having reviewed the other commitments and contingencies which exist, the Trustees consider that it is appropriate to set aside reserves equivalent to 6 months operating costs in order to enable an orderly wind-up of the organisation, plus a further £2m to fund research work to ensure that projects can be brought to a successful conclusion in the event of a significant reduction in income and reserves. At the present time, the reserves required by this policy would be approximately £2.55m against free reserves at the year-end of £3.4m. The Charity does not designate funds for specific purposes and restricted funds are minimal. The reserves are held in cash and investments and are not held in fixed assets.

At the present time the organisation has funds above its current reserves target and it will continue to utilise this to fund research at a rate quicker than revenue would normally allow.

PLANS FOR THE FUTURE

In light of the Covid-19 pandemic, the Trustees have looked closely at our targets for the year to ensure that these are flexible and adaptable to the rapidly changing situation. Key targets for 2020/21 include:

- To complete the review of our strategy and to align both our work and our funded research with it: ensuring that we focus all of our efforts on the cancer needs of the region;
- When it is safe to do so, to re-establish our fundraising work, including a vibrant events programme - alongside our Committees to minimise any longer-term impact for them;
- To work with academic and health partners across the region and beyond to ensure that we establish new routes to undertake research which enables us to understand cancer, its causes and impacts in our region;
- To develop partnerships with other research funders to maximise the resources available to the sector; and
- To develop and grow our information and outreach work to ensure that more people in our region are aware of the causes of cancer and the measures which can be taken to reduce our risks.

NORTH WEST CANCER RESEARCH (INCORPORATING CLATTERBRIDGE CANCER RESEARCH “CCR”)

(A company limited by guarantee)

TRUSTEES’ REPORT FOR THE YEAR ENDED 30 SEPTEMBER 2020 (continued)

TRUSTEES’ RESPONSIBILITIES STATEMENT

The Trustees (who are also directors of North West Cancer Research (incorporating Clatterbridge Cancer Research “CCR”) for the purposes of company law are responsible for preparing the Trustees’ Report and the Financial Statements in accordance with applicable law and United Kingdom Accounting Standards (United Kingdom Generally Accepted Accounting Practice).

Company law requires the Trustees to prepare Financial Statements for each financial year. Under company law the Trustees must not approve the Financial Statements unless they are satisfied that they give a true and fair view of the state of affairs of the charitable company and of the incoming resources and application of resources, including the income and expenditure, of the charitable company for that period.

In preparing these Financial Statements, the Trustees are required to:

- Select suitable accounting policies and then apply them consistently;
- Observe the methods and principles in the Charities SORP;
- Make judgements and accounting estimates that are reasonable and prudent; and
- Prepare the Financial Statements on a going concern basis unless it is inappropriate to presume that the charitable company will continue in operation.

The Trustees are responsible for keeping adequate accounting records that are sufficient to show and explain the charitable company’s transactions and disclose with reasonable accuracy at any time the financial position of the charitable company and enable them to ensure that the Financial Statements comply with the Companies Act 2006. They are also responsible for safeguarding the assets of the charitable company and hence for taking reasonable steps for the prevention and detection of fraud and other irregularities.

During the year, the Trustees reviewed the Charity Governance Code in order to consider the current governance arrangements in place and whether these could be improved. A number of small areas of improvement were identified which will be reconsidered in the coming year.

**NORTH WEST CANCER RESEARCH (INCORPORATING CLATTERBRIDGE CANCER
RESEARCH “CCR”)**

(A company limited by guarantee)

**TRUSTEES’ REPORT
FOR THE YEAR ENDED 30 SEPTEMBER 2020 (continued)**

DISCLOSURE OF INFORMATION TO AUDITOR

Each of the persons who are Trustees at the time when this Trustees’ Report is approved has confirmed that:

- So far as that Trustee is aware, there is no relevant audit information of which the charitable Company’s Auditor is unaware; and
- That Trustee has taken all steps that ought to have been taken as a Trustee in order to be aware of any information needed by the charitable Company’s Auditor in connection with preparing its reports and to establish that the charitable Company’s Auditor is aware of that information.

AUDITOR

The Auditor, Crowe U.K. LLP, has indicated its willingness to continue in office.

This report was approved by the Trustees on 25 January 2021 and signed on their behalf by:



**Mr N S Lanceley
Chairman**

**INDEPENDENT AUDITOR'S REPORT TO THE MEMBERS OF NORTH WEST CANCER RESEARCH
(INCORPORATING CLATTERBRIDGE CANCER RESEARCH "CCR")**

OPINION

We have audited the Financial Statements of North West Cancer Research (Incorporating Clatterbridge Cancer Research "CCR") for the year ended 30 September 2020 which comprise the Consolidated Statement of Financial Activities, the Consolidated and Charity Balance Sheets and the Consolidated Cash Flow Statement and notes to the Financial Statements, including a summary of significant accounting policies. The financial reporting framework that has been applied in their preparation is applicable law and United Kingdom Accounting Standards, including Financial Reporting Standard 102, the Financial Reporting Standard applicable in the UK and Republic of Ireland (United Kingdom Generally Accepted Accounting Practice).

In our opinion the Financial Statements:

- give a true and fair view of the state of the Group's and the charitable Company's affairs as at 30 September 2020 and of the Group's incoming resources and application of resources, including its income and expenditure for the year then ended;
- have been properly prepared in accordance with United Kingdom Generally Accepted Accounting Practice; and
- have been prepared in accordance with the requirements of the Companies Act 2006 and the Charities Act 2011.

BASIS FOR OPINION

We conducted our audit in accordance with International Standards on Auditing (UK) (ISAs (UK)) and applicable law. Our responsibilities under those standards are further described in the auditor's responsibilities for the audit of the Financial Statements section of our report. We are independent of the Group in accordance with the ethical requirements that are relevant to our audit of the Financial Statements in the UK, including the FRC's Ethical Standard, and we have fulfilled our other ethical responsibilities in accordance with these requirements. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.

CONCLUSIONS RELATING TO GOING CONCERN

We have nothing to report in respect of the following matters in relation to which the ISAs (UK) require us to report to you where:

- the Trustees' use of the going concern basis of accounting in the preparation of the Financial Statements is not appropriate; or
- the Trustees have not disclosed in the Financial Statements any identified material uncertainties that may cast significant doubt about the Group's or the charitable Company's ability to continue to adopt the going concern basis of accounting for a period of at least twelve months from the date when the Financial Statements are authorised for issue.

**INDEPENDENT AUDITOR'S REPORT TO THE MEMBERS OF NORTH WEST CANCER RESEARCH
(INCORPORATING CLATTERBRIDGE CANCER RESEARCH "CCR")**

OTHER INFORMATION

The Trustees are responsible for the other information. The other information comprises the information included in the Annual Report, other than the Financial Statements and our Auditor's Report thereon. Our opinion on the Financial Statements does not cover the other information and, except to the extent otherwise explicitly stated in our report, we do not express any form of assurance conclusion thereon.

In connection with our audit of the Financial Statements, our responsibility is to read the other information and, in doing so, consider whether the other information is materially inconsistent with the Financial Statements or our knowledge obtained in the audit or otherwise appears to be materially misstated. If we identify such material inconsistencies or apparent material misstatements, we are required to determine whether there is a material misstatement in the Financial Statements or a material misstatement of the other information. If, based on the work we have performed, we conclude that there is a material misstatement of this other information, we are required to report that fact.

We have nothing to report in this regard.

OPINION ON OTHER MATTERS PRESCRIBED BY THE COMPANIES ACT 2006

In our opinion based on the work undertaken in the course of our audit:

- the information given in the Trustees' Report, which includes the Directors' Report prepared for the purposes of company law, for the financial year for which the Financial Statements are prepared is consistent with the financial statements; and
- the Directors' Report included within the Trustees' Report has been prepared in accordance with applicable legal requirements.

MATTERS ON WHICH WE ARE REQUIRED TO REPORT BY EXCEPTION

In light of the knowledge and understanding of the Group and the Charitable company and their environment obtained in the course of the audit, we have not identified material misstatements in the Directors' Report included within the Trustees' Report.

**INDEPENDENT AUDITOR'S REPORT TO THE MEMBERS OF NORTH WEST CANCER RESEARCH
(INCORPORATING CLATTERBRIDGE CANCER RESEARCH "CCR")**

MATTERS ON WHICH WE ARE REQUIRED TO REPORT BY EXCEPTION (continued)

We have nothing to report in respect of the following matters in relation to which the Companies Act 2006 requires us to report to you if, in our opinion:

- the parent Company has not kept adequate accounting records; or
- the parent Company Financial Statements are not in agreement with the accounting records and returns; or
- certain disclosures of Trustees' remuneration specified by law are not made; or
- we have not received all the information and explanations we require for our audit; or
- the Trustees were not entitled to prepare the Financial Statements in accordance with the small companies regime and take advantage of the small companies exemption in preparing the Trustees' Annual Report.

RESPONSIBILITIES OF TRUSTEES

As explained more fully in the Trustees' Responsibilities Statement set out on page 17, the Trustees (who are also the Directors of the charitable Company for the purposes of company law) are responsible for the preparation of the Financial Statements and for being satisfied that they give a true and fair view, and for such internal control as the Trustees determine is necessary to enable the preparation of Financial Statements that are free from material misstatement, whether due to fraud or error.

In preparing the Financial Statements, the Trustees are responsible for assessing the Group's or the charitable Company's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless the Trustees either intend to liquidate the charitable Company or to cease operations, or have no realistic alternative but to do so.

AUDITOR'S RESPONSIBILITY FOR THE AUDIT OF THE FINANCIAL STATEMENTS

We have been appointed as Auditor under section 151 of the Charities Act 2011 and under the Companies Act 2006 and report in accordance with the Acts and relevant regulations made or having effect thereunder.

**INDEPENDENT AUDITOR'S REPORT TO THE MEMBERS OF NORTH WEST CANCER RESEARCH
(INCORPORATING CLATTERBRIDGE CANCER RESEARCH "CCR")**

AUDITOR'S RESPONSIBILITY FOR THE AUDIT OF THE FINANCIAL STATEMENTS (CONTINUED)

Our objectives are to obtain reasonable assurance about whether the Financial Statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an Auditor's Report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with ISAs (UK) will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these Financial Statements.

A further description of our responsibilities for the audit of the Financial Statements is located on the Financial Reporting Council's website at: www.frc.org.uk/auditorsresponsibilities. This description forms part of our Auditor's Report.

USE OF OUR REPORT

This report is made solely to the charitable Company's members, as a body, in accordance with Chapter 3 of part 16 of the Companies Act 2006, and to the charitable Company's Trustees, as a body, in accordance with Part 4 of the Charities (Accounts and Reports) Regulations 2008. Our audit work has been undertaken so that we might state to the charitable Company's members and Trustees those matters we are required to state to them in an Auditor's Report and for no other purpose. To the fullest extent permitted by law, we do not accept or assume responsibility to anyone other than the charitable Company, the charitable Company's members as a body and the charitable Company's Trustees as a body, for our audit work, for this report, or for the opinions we have formed.



Michael Jayson
Senior Statutory Auditor
For and on behalf of
Crowe U.K. LLP
Statutory Auditor

The Lexicon
Mount Street
Manchester
M2 5NT

25 January 2021

NORTH WEST CANCER RESEARCH (INCORPORATING CLATTERBRIDGE CANCER RESEARCH "CCR")

(A company limited by guarantee)

REGISTERED NUMBER: 2165552

**CONSOLIDATED STATEMENT OF FINANCIAL ACTIVITIES
(INCORPORATING THE INCOME AND EXPENDITURE ACCOUNT)
FOR THE YEAR ENDED 30 SEPTEMBER 2010**

	Note	Unrestricted and total funds 2020 £	Restricted funds 2020 £	Total funds 2020 £	<i>Total funds 2019 £</i>
INCOME FROM:					
Donations and legacies	2	1,327,439	3,000	1,330,439	1,389,300
Investment income	3	211,552	-	211,552	410,955
TOTAL INCOME		1,538,991	3,000	1,541,991	1,800,255
EXPENDITURE ON:					
Raising funds:					
Fundraising and legacy generation costs		509,029	-	509,029	670,520
Investment management		33,714	-	33,714	48,309
Charitable activities	6	1,629,963	3,225	1,633,188	3,104,952
TOTAL EXPENDITURE	6	2,172,706	3,225	2,175,931	3,823,781
NET EXPENDITURE BEFORE INVESTMENT GAINS		(633,715)	(225)	(633,940)	(2,023,526)
(Losses)/Gains on investments		(234,701)	-	(234,701)	93,325
NET EXPENDITURE BEFORE TRANSFERS		(868,416)	(225)	(868,641)	(1,930,201)
Transfers between funds		-	-	-	-
NET MOVEMENT IN FUNDS		(868,416)	(225)	(868,641)	(1,930,201)
RECONCILIATION OF FUNDS:					
Total funds brought forward		4,276,004	3,559	4,279,563	6,209,764
TOTAL FUNDS CARRIED FORWARD		3,407,588	3,334	3,410,922	4,279,563

The notes on pages 27 to 47 form part of the Financial Statements.

NORTH WEST CANCER RESEARCH (INCORPORATING CLATTERBRIDGE CANCER RESEARCH "CCR")

(A company limited by guarantee)

REGISTERED NUMBER: 2165552

CONSOLIDATED BALANCE SHEET AS AT 30 SEPTEMBER 2020

	Note	£	2020 £	£	2019 £
FIXED ASSETS					
Tangible assets	10		5,917		7,568
Investments	11		9,423,465		10,132,177
			9,429,382		10,139,745
CURRENT ASSETS					
Stocks	12	17,126		10,142	
Debtors	13	679,710		676,672	
Cash at bank and in hand		727,250		295,214	
			1,424,086	982,028	
CREDITORS: amounts falling due in less than one year	14		(4,934,713)	(3,484,225)	
NET CURRENT LIABILITIES			(3,510,627)	(2,502,198)	
TOTAL ASSETS LESS CURRENT LIABILITIES			5,918,755	7,637,547	
CREDITORS: amounts falling due after more than one year	15		(2,507,833)	(3,357,985)	
NET ASSETS			3,410,922	4,279,563	
CHARITY FUNDS					
Restricted funds	17		3,334		3,559
Unrestricted funds	17		3,407,588		4,276,004
TOTAL FUNDS			3,410,922	4,279,563	

The Company's Financial Statements have been prepared in accordance with the provisions applicable to companies subject to the small companies regime. The Financial Statements were approved and authorised for review by the Trustees on 25 January 2021 and signed on their behalf, by:



Mrs C Bond CPFA, Honorary Treasurer



Mr N S Lanceley FCA, Chairman

The notes on pages 27 to 47 form part of these Financial Statements.

NORTH WEST CANCER RESEARCH (INCORPORATING CLATTERBRIDGE CANCER RESEARCH "CCR")

(A company limited by guarantee)

CHARITY BALANCE SHEET AS AT 30 SEPTEMBER 2020

	Note	£	2020 £	£	2019 £
FIXED ASSETS					
Tangible assets	10		5,917		7,568
Investments	11		9,288,498		9,989,491
			9,294,415		9,997,059
CURRENT ASSETS					
Stocks	12	17,126		10,142	
Debtors	13	691,460		634,867	
Cash at bank and in hand		667,320		282,801	
			1,375,906	927,810	
CREDITORS: amounts falling due in less than one year	14		(4,932,913)	(3,484,226)	
NET CURRENT LIABILITIES			(3,557,007)	(2,556,416)	
TOTAL ASSETS LESS CURRENT LIABILITIES			5,737,408	7,440,643	
CREDITORS: amounts falling due after more than one year	15		(2,507,833)	(3,357,985)	
NET ASSETS			3,229,575	4,082,658	
CHARITY FUNDS					
Restricted funds	17		3,334		3,559
Unrestricted funds	17		3,226,241	4,079,099	
TOTAL FUNDS			3,229,575	4,082,658	

The Company's Financial Statements have been prepared in accordance with the provisions applicable to companies subject to the small companies regime. The Financial Statements were approved and authorised for review by the Trustees on 25th January 2021 and signed on their behalf, by:


Mrs C Bond CPFA, Honorary Treasurer


Mr N S Lancelley FCA, Chairman

The notes on pages 27 to 47 form part of these Financial Statements

**NORTH WEST CANCER RESEARCH (INCORPORATING CLATTERBRIDGE CANCER
RESEARCH “CCR”)**

(A company limited by guarantee)

**CONSOLIDATED STATEMENT OF CASH FLOWS
FOR THE YEAR ENDED 30 SEPTEMBER 2020**

	Note	2020 £	2019 £
Cash flows from operating activities:			
Net cash used in operating activities	19	(252,145)	(1,622,848)
Cash flows from investing activities:			
Dividends and interest from investments		211,551	410,955
Purchase of tangible fixed assets		-	(8,256)
Write off value of fixed assets		-	-
Cash acquired		-	-
Proceeds from the sale of investments		6,542,334	2,924,485
Purchase of investments		(5,893,256)	(2,571,543)
Net cash provided by investing activities		860,629	755,641
Change in cash and cash equivalents in the year		608,484	(867,207)
Cash and cash equivalents brought forward		642,433	1,509,640
Cash and cash equivalents carried forward	20	1,250,917	642,433

NORTH WEST CANCER RESEARCH (INCORPORATING CLATTERBRIDGE CANCER RESEARCH “CCR”)

(A company limited by guarantee)

1. ACCOUNTING POLICIES

1.1 Basis of preparation of Financial Statements

The Financial Statements have been prepared in accordance with Accounting and Reporting by Charities: Statement of Recommended Practice applicable to charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102) (effective 1 January 2015) – (Charities SORP (FRS 102)), the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102) and the Companies Act 2006.

North West Cancer Research (incorporating Clatterbridge Cancer Research “CCR”) meets the definition of a public benefit entity under FRS 102. Assets and liabilities are initially recognised at historical cost or transaction value unless otherwise stated in the relevant accounting policy.

The accompanying Consolidated Financial Statements include the Financial Statements of North West Cancer Research, and its consolidated subsidiaries (together referred to as the Charity). NWCR’s subsidiaries are listed in note 11.

No separate SOFA has been presented for the Charity alone as permitted by section 408 of the Companies Act 2006.

NWCR was created by merger of two charities: Clatterbridge Cancer Research and North West Cancer Research Fund. The principal object and activity of both charities was to promote and carry out research into cancer. The merger took effect from 1 November 2012.

1.2 Company status

The Company is a company limited by guarantee. The members of the Company are the Trustees named on page 3. In the event of the Company being wound up, the liability in respect of the guarantee is limited to £1 per member of the Company.

1.3 Going concern

The Financial Statements have been prepared on a going concern basis, which principally assumes that the Company will continue to receive an adequate level of income to meet its anticipated requirements. This has been reviewed in light of the Covid-19 pandemic and the impact that this is having on the Charity’s fundraising activities along with the impact on investments and reserves. The Trustees have adopted prudent plans and have reduced commitments to new research funding accordingly in order to ensure that any financial impacts are minimised.

On that basis the Trustees consider it appropriate to prepare the Financial Statements on a going concern basis.

NORTH WEST CANCER RESEARCH (INCORPORATING CLATTERBRIDGE CANCER RESEARCH “CCR”)

(A company limited by guarantee)

1. ACCOUNTING POLICIES (continued)

1.4 Consolidated Financial Statements

These Financial Statements consolidate the results of the Charity and its subsidiary undertaking. The consolidation has been undertaken on a line by line basis.

The Charity has taken advantage of the exemption available to a qualifying entity in FRS 102 from the requirement to present a Charity only Cash Flow Statement with the consolidated accounts.

1.5 Income

All income is recognised once the Company has entitlement to the income, it is probable that the income will be received and the amount of income receivable can be measured reliably.

For legacies, entitlement is taken as the earlier of the date on which either: the Company is aware that probate has been granted, the estate has been finalised and notification has been made by the executor(s) to the Trust that a distribution will be made, or when a distribution is received from the estate. Receipt of a legacy, in whole or in part, is only considered probable when the amount can be measured reliably and the Company has been notified of the executor’s intention to make a distribution. Where legacies have been notified to the Company, or the Company is aware of the granting of probate, and the criteria for income recognition have not been met, then the legacy is treated as a contingent asset and disclosed if material.

Donated services or facilities are recognised when material and the Company has control over the item, any conditions associated with the donated item have been met, the receipt of the economic benefit from the use of the Company of the item is probable and that economic benefit can be measured reliably. In accordance with the Charities SORP (FRS 102), the general volunteer time of the branches / committees is not recognised – reference should be made to the Trustees’ Report for more information about their contribution.

On receipt, donated professional services and donated facilities are recognised on the basis of the value of the gift to the Company which is the amount the Company would have been willing to pay to obtaining services or facilities of equivalent economic benefit on the open market; a corresponding amount is then recognised in expenditure in the period of receipt.

Income tax recoverable in relation to donations received under Gift Aid or deeds of covenant is recognised at the time of the donation.

Income tax recoverable in relation to investment income is recognised at the time the investment income is receivable.

NORTH WEST CANCER RESEARCH (INCORPORATING CLATTERBRIDGE CANCER RESEARCH “CCR”)

(A company limited by guarantee)

1. ACCOUNTING POLICIES (continued)

1.6 Expenditure

Expenditure is recognised once there is a legal or constructive obligation to transfer economic benefit to a third party, it is probable that a transfer of economic benefits will be required in settlement and the amount of the obligation can be measured reliably. Expenditure is classified by activity. The costs of each activity are made up of the total of direct costs and shared costs, including support costs involved in undertaking each activity. Direct costs attributable to a single activity are allocated directly to that activity. Shared costs which contribute to more than one activity and support costs which are not attributable to a single activity are apportioned between those activities on a basis consistent with the use of resources. Central staff costs are allocated on the basis of time spent.

Fundraising costs are those incurred in seeking voluntary contributions and do not include the costs of disseminating information in support of the charitable activities. Support costs are those costs incurred directly in support of expenditure on the objects of the Company and include project management carried out at headquarters. Governance costs are those incurred in connection with administration of the Company and compliance with constitutional and statutory requirements.

Costs of generating funds are costs incurred in attracting voluntary income, and those incurred in trading activities that raise funds.

Charitable activities and Governance costs are costs incurred on the Company's charitable operations, including support costs and costs relating to the governance of the Company apportioned to charitable activities.

Grants payable are charged in the year when the offer is made except, in those cases where the offer is conditional, such grants being recognised as expenditure when the conditions attached are fulfilled.

All resources expended are inclusive of irrecoverable VAT.

1.7 Tangible fixed assets and depreciation

All assets costing more than £1,000 are capitalised.

Tangible fixed assets are carried at cost, net of depreciation and any provision for impairment.

NORTH WEST CANCER RESEARCH (INCORPORATING CLATTERBRIDGE CANCER RESEARCH “CCR”)

(A company limited by guarantee)

1. ACCOUNTING POLICIES (continued)

1.8 Tangible fixed assets and depreciation (continued)

Depreciation is provided at rates calculated to write off the cost of fixed assets, less their estimated residual value, over their expected useful lives on the following bases:

Office equipment	-	5 years straight line
Computer equipment	-	4 years straight line

1.9 Investments

Fixed asset investments are a form of financial instrument and are initially recognised at their transaction cost and subsequently measured at their fair value at the balance sheet date, unless fair value cannot be measured reliably, in which case it is measured at cost less impairment.

Investment gains and losses, whether realised or unrealised, are combined and shown in the heading ‘Gains / (losses) on Investments’ in the Statement of Financial Activities.

1.10 Interest receivable

Interest on funds held on deposit is included when receivable and the amount can be measured reliably by the Company; this is normally upon notification of the interest paid or payable by the Bank.

1.11 Operating leases

Rentals under operating leases are charged to the Statement of Financial Activities on a straight line basis over the lease term.

1.12 Stocks

Stocks are valued at the lower of cost and net realisable value after making due allowance for obsolete and slow-moving stocks.

1.13 Debtors

Trade and other debtors are recognised at the settlement amount after any trade discount offered. Prepayments are valued at the amount prepaid net of any trade discounts due.

NORTH WEST CANCER RESEARCH (INCORPORATING CLATTERBRIDGE CANCER RESEARCH “CCR”)

(A company limited by guarantee)

1. ACCOUNTING POLICIES (continued)

1.14 Cash at Bank and in hand

Cash at bank and in hand includes cash and short term highly liquid investments with a short maturity of three months or less from the date of acquisition or opening of the deposit or similar account.

1.15 Liabilities and provisions

Liabilities are recognised when there is an obligation at the balance sheet date as a result of a past event, it is probable that a transfer of economic benefit will be required in settlement, and the amount of the settlement can be estimated reliably. Liabilities are recognised at the amount that the Company anticipates it will pay to settle the debt or the amount it has received as advanced payment for the goods and services it must provide. Provisions are measured at the best estimate of the amounts required to settle the obligation.

1.16 Financial instruments

The Company only has financial assets and financial liabilities of a kind that qualify as basic financial instruments. Basic financial instruments are initially recognised at transaction value and subsequently measured at their settlement date.

1.17 Pensions

The Company contributes to personal pension plans and the pension charge represents the amounts payable by the Company to the plans in respect of the period.

1.18 Fund accounting

General funds are unrestricted funds which are available for the use at the discretion of the Trustees in furtherance of the general objectives of the Company and which have not been designated for other purposes.

Restricted funds are funds which are to be used in accordance with specific restrictions imposed by donors or which have been raised by the Company for particular purposes. The costs of raising and administering such funds are charged against the specific fund. The aim and use of each restricted fund is set out in the notes to the Financial Statements.

Where the effect of the time value of money is material, the provision is based on the present value of those amounts, discounted at the pre-tax discount rate that reflects the risks specific to the liability. The unwinding of the discount rate is recognised within interest payable and similar charges.

NORTH WEST CANCER RESEARCH (INCORPORATING CLATTERBRIDGE CANCER RESEARCH "CCR")

(A company limited by guarantee)

1. ACCOUNTING POLICIES (continued)

1.19 Critical accounting judgements and estimates

The key source of estimation uncertainty in the Financial Statements are residuary legacies. Legacies are recognised when the income criteria detailed in note 1.5 are considered to be met. In some circumstances, the legacy has not been received at the year end and is included within debtors. Due to the nature of residuary legacies receivable, there is judgement applied to the valuation of the legacy.

Where the effect of the time value of money is material to liabilities and provisions, the liability or provision is based on the present value of those amounts, discounted at the pre-tax discount rate that reflects the risks specific to the liability. The unwinding of the discount rate is recognised within interest payable and similar charges. In the 2019/20 Financial Statements there were no instances where the time value of money was material and therefore no discounting has taken place.

The estimates and underlying assumptions are reviewed regularly. Revisions to accounting estimates are recognised in the period in which the estimate is revised where the revision affects only that period, or in the period of the revision and future periods where the revision affects both current and future periods.

2. INCOME FROM DONATIONS AND LEGACIES

Group and Charity	Unrestricted	Restricted	Total
	and total funds 2020 £		
Legacies	920,594	-	920,594
Donations	315,613	3,000	318,613
Donations-in-kind	39,867	-	39,867
Coronavirus Job Retention Scheme Grant	51,365	-	51,365
Total donations and legacies	<u>1,327,439</u>	<u>3,000</u>	<u>1,330,439</u>

NORTH WEST CANCER RESEARCH (INCORPORATING CLATTERBRIDGE CANCER RESEARCH "CCR")

(A company limited by guarantee)

Group and Charity	Unrestricted and total funds 2019 £	Restricted funds 2019 £	Total funds 2019 £
Legacies	778,373	-	778,373
Donations	555,216	4,000	559,216
Donations-in-kind	51,711	-	51,711
Total donations and legacies	1,385,300	4,000	1,389,300

3. INVESTMENT INCOME

Group and Charity	Unrestricted and total funds 2020 £	Restricted funds 2020 £	Total funds 2020 £
Investment income – listed investments	211,111	-	211,111
Investment income – cash investments	441	-	441
	211,552	-	211,552

Group and Charity	Unrestricted and total funds 2019 £	Restricted funds 2019 £	Total funds 2019 £
Investment income – listed investments	324,570	-	324,570
Investment income – cash investments	86,385	-	86,385
	410,955	-	410,955

NORTH WEST CANCER RESEARCH (INCORPORATING CLATTERBRIDGE CANCER RESEARCH "CCR")

(A company limited by guarantee)

4. ANALYSIS OF GRANTS

Group and Charity	Grants to Institutions 2020 £	Unrestricted and total funds 2020 £	<i>Unrestricted and total funds 2019 £</i>
Grants approved in the year	1,282,543	1,282,543	2,750,242

The total above of £1,282,543 (2019: £2,750,242, includes £0 (2019: £13,000) paid to Liverpool Medical Institute Library for the purchase of books and other non-salary related support costs of £11,083 (2019: £73,394).

As disclosed in Note 6, Analysis of Resources Expended by Expenditure Type, the Research Grant Expenditure charged in the Statement of Financial Activities associated staff costs of £170,223 (2019: £101,794).

RECONCILIATION OF GRANTS PAYABLE

	2020 £	2019 £
Accrued at 1 October 2019	6,355,666	5,173,397
Grants made in the year – Liverpool	548,325	2,036,811
Grants made in the year – Lancaster	572,127	351,484
Grants made in the year – Bangor	27,000	67,301
Grants made in the year – Chester	-	294,646
Grants made in the year -- Blackpool	129,055	-
Grants cancelled or recovered	(5,047)	(17,257)
Grants paid and other movements	(967,475)	(1,550,716)
Accrued at 30 September 2020	6,659,651	6,355,666
Payable as follows:		
Grants payable <1yr – institutional	4,151,818	2,997,681
Grants payable >1yr – institutional	2,507,833	3,357,985
Total grants payable	6,659,651	6,355,666

NORTH WEST CANCER RESEARCH (INCORPORATING CLATTERBRIDGE CANCER RESEARCH "CCR")

(A company limited by guarantee)

5. GOVERNANCE COSTS

Group and Charity	Unrestricted and total funds 2020 £	Restricted funds 2020 £	Total funds 2020 £
Governance Auditor's remuneration	14,040	-	14,040
Governance legal and professional fees	12,247	-	12,247
Governance share of support costs	30,640	-	30,640
Governance expense – recruitment fees	2,162	-	2,162
Governance expense – wages and salaries	61,141	-	61,141
Governance – depreciation – tangible fixed assets	201	-	201
	120,431	-	120,431

Group and Charity	Unrestricted and total funds 2019 £	Restricted funds 2019 £	Total funds 2019 £
Governance Auditor's remuneration	9,960	-	9,960
Governance legal and professional fees	10,745	-	10,745
Governance share of support costs	43,720	-	43,720
Governance expense – Scientific Expenditure	1,214	-	1,214
Governance expense – recruitment fees	1,752	-	1,752
Governance expense – wages and salaries	81,726	-	81,726
Governance – depreciation – tangible fixed assets	105	-	105
	149,222	-	149,222

NORTH WEST CANCER RESEARCH (INCORPORATING CLATTERBRIDGE CANCER RESEARCH "CCR")

(A company limited by guarantee)

6. ANALYSIS OF RESOURCES EXPENDED BY EXPENDITURE TYPE

Group and Charity	Staff costs 2020 £	Depreciation 2020 £	Other costs 2020 £	Total 2020 £
Expenditure of fundraising	271,869	892	236,268	509,029
Expenditure on investment management	-	-	33,714	33,714
Cost of generating funds	271,869	892	269,982	542,743
Research grant expenditure	170,223	558	1,341,975	1,512,757
Expenditure on governance	61,141	201	59,090	120,431
Charitable activities	231,364	759	1,401,065	1,633,188
	503,233	1,651	1,671,046	2,175,930

Group and Charity	Staff costs 2019 £	Depreciation 2019 £	Other costs 2019 £	Total 2019 £
Expenditure of fundraising	352,695	453	317,372	670,520
Expenditure on investment management	-	-	48,309	48,309
Cost of generating funds	352,695	453	365,681	718,829
Research grant expenditure	101,794	130	2,853,807	2,955,731
Expenditure on governance	81,726	105	67,390	149,221
Charitable activities	183,530	235	2,921,197	3,104,952
	536,215	688	3,286,878	3,823,781

NORTH WEST CANCER RESEARCH (INCORPORATING CLATTERBRIDGE CANCER RESEARCH “CCR”)

(A company limited by guarantee)

7. NET EXPENDITURE

This is stated after charging:

	2020	2019
	£	£
Depreciation of tangible fixed assets: owned by the Charity	1,651	688
Auditor’s remuneration – audit	12,240	9,960
	<u>12,240</u>	<u>9,960</u>

During the year, no Trustees received any remuneration (2019: £0).

During the year, no Trustees received any benefits in kind (2019: £0).

During the year, one Trustee received reimbursement of travel and accommodation expenses totalling £866 (2019: one Trustee received reimbursement of travel expenses totalling £738).

8. AUDITOR’S REMUNERATION

The Auditor’s remuneration amounts to an audit fee of £12,240 (2019: £9,960).

NORTH WEST CANCER RESEARCH (INCORPORATING CLATTERBRIDGE CANCER RESEARCH "CCR")

(A company limited by guarantee)

9. STAFF COSTS

Staff costs were as follows:

	2020	2019
	£	£
Wages and salaries	438,657	463,527
Social security costs	41,892	42,565
Other pension costs	22,683	30,123
	<u>503,232</u>	<u>536,215</u>

The average number of persons (headcount) employed by the Company during the year was as follows:

	2020	2019
	No.	No.
Fundraising and marketing	10	10
Administration	5	5
	<u>15</u>	<u>15</u>

The Trustees have delegated significant authority and responsibility in the day-to-day running of the Charity to its key management personnel. The Charity considers its key management personnel to comprise the Chief Executive Officer, Head of Finance and Administration, Head of Fundraising and the Head of Marketing and Communications. The total employee benefits including employer pension contributions of the key management personnel were £215,488 (2019: £230,369).

One employee had employee benefits in the range of £70,000 to £80,000 (2019: £70,000 to £80,000) but during the year made donations back to the Charity of £6,628 before gift aid.

An ex-gratia payment of £0 (2019: £500) was made to a former employee.

**NORTH WEST CANCER RESEARCH (INCORPORATING CLATTERBRIDGE CANCER
RESEARCH “CCR”)**

(A company limited by guarantee)

10. TANGIBLE FIXED ASSETS

Group and Charity	Fixtures and fittings £	Total £
Cost		
At 1 October 2019	8,256	8,256
At 30 September 2020	<u>8,256</u>	<u>8,256</u>
Depreciation		
At 1 October 2019	688	688
Charge for the year	1,651	1,651
At 30 September 2020	<u>2,339</u>	<u>2,339</u>
Net book value		
At 30 September 2020	<u>5,917</u>	<u>5,917</u>
At 30 September 2019	<u>7,568</u>	<u>7,568</u>

11. FIXED ASSET INVESTMENTS

Group	Listed securities (Market value) £	Cash £	Total £
At 1 October 2019	9,784,958	347,219	10,132,177
Additions	5,893,256	-	5,893,256
Disposals	(6,542,334)	-	(6,542,334)
Movement in cash for the year	1,256	176,448	177,704
Realised and unrealised gains on investments	(237,338)	-	(237,338)
At 30 September 2020	<u>8,899,798</u>	<u>523,667</u>	<u>9,423,465</u>

NORTH WEST CANCER RESEARCH (INCORPORATING CLATTERBRIDGE CANCER RESEARCH "CCR")

(A company limited by guarantee)

11. FIXED ASSET INVESTMENTS (continued)

Company	Listed securities (Market value) £	Cash £	Shares in group undertakings £	Total £
At 1 October 2019	9,642,272	347,219	1	9,989,491
Additions	5,893,256	-	-	5,893,256
Disposals	(6,542,334)	-	-	(6,542,334)
Movement in cash for the year		176,448	-	176,448
Realised and unrealised gains on investments	(228,364)	-	-	(228,364)
At 30 September 2020	8,764,831	523,667	1	9,288,498

Group subsidiary undertakings

The following were subsidiary undertakings of the Company:

Name	Holding
Clatterbridge Cancer Research Limited	100%
Cancer and Polio Research Fund Limited	100%

The aggregate of the share capital and reserves as at 30 September 2020 and of the profit or loss for the year ended related to the Charity's subsidiary undertakings were as follows:

Name	Aggregate of share capital and reserves £	Profit / (loss) £
Clatterbridge Cancer Research Limited	1	
Cancer and Polio Research Fund Limited	181,347	(15,557)
Total	181,348	(15,557)

NORTH WEST CANCER RESEARCH (INCORPORATING CLATTERBRIDGE CANCER RESEARCH “CCR”)

(A company limited by guarantee)

11. FIXED ASSET INVESTMENTS (continued)

Group and Charity material restrictions

The Company has barred investment in tobacco businesses. As members of the Association of Medical Research Charities, we follow their ethical guidelines for research. Investments are primarily held to provide a balance between capital growth and income in order to meet the Company’s future commitments.

12. STOCKS

	Group		<i>Charity</i>	
	2020	<i>2019</i>	2020	<i>2019</i>
	£	£	£	£
Goods for resale	17,126	10,142	17,126	10,142
	17,126	10,142	17,126	10,142

13. DEBTORS

	Group		<i>Charity</i>	
	2020	<i>2019</i>	2020	<i>2019</i>
	£	£	£	£
Other debtors	5,500	4,856	5,500	16,242
Prepayments and accrued income	674,210	671,816	685,960	618,625
	679,710	676,672	691,460	634,867
	679,710	676,672	691,460	634,867

NORTH WEST CANCER RESEARCH (INCORPORATING CLATTERBRIDGE CANCER RESEARCH "CCR")

(A company limited by guarantee)

14. CREDITORS: Amounts falling due within one year

	Group		Charity	
	2020	2019	2020	2019
	£	£	£	£
Trade creditors	712,907	50,806	712,907	50,806
Sundry creditors	465	2,502	465	2,502
Amounts owed to CCR, the subsidiary company	-	-	1	1
Other taxation and social security	14,581	11,868	14,581	11,868
Accruals and deferred income	54,942	421,367	53,142	421,367
Grants accrued – institutional (see note 4)	4,151,818	2,997,682	4,151,818	2,997,682
	4,934,713	3,484,225	4,932,913	3,484,226

15. CREDITORS: Amounts falling due after more than one year

	Group		Charity	
	2020	2019	2020	2019
	£	£	£	£
Grants accrued – institutional (see note 4)	2,507,833	3,357,985	2,507,833	3,357,985

16. FINANCIAL INSTRUMENTS

	Group		Charity	
	2020	2019	2020	2019
	£	£	£	£
Financial assets measured at fair value				
Investments	9,423,465	9,989,492	9,288,497	10,919,174
Financial assets measured at amortised cost				
Debtors excluding prepayments	654,786	234,945	666,536	634,867
Financial liabilities measured at amortised cost				
Creditors	7,442,546	6,842,211	7,440,746	6,842,211

NORTH WEST CANCER RESEARCH (INCORPORATING CLATTERBRIDGE CANCER RESEARCH "CCR")

(A company limited by guarantee)

17. STATEMENT OF FUNDS

GROUP STATEMENT OF FUNDS – CURRENT YEAR

	Balance at 1 October 2019 £	Income £	Expenditure £	Gains / (Losses) £	Balance at 30 September 2020 £
Unrestricted and total funds					
Other General funds	4,276,004	1,538,991	(2,172,706)	(234,701)	3,407,588
Restricted funds					
Other restricted funds	3,559	3,000	(3,225)	-	3,334
Total of funds	4,279,563	1,541,991	(2,175,931)	(234,701)	3,410,922

The restricted funds received during the year of £3,000 was a grant from Groundwork UK, restricted to use specifically for lab coat learning.

GROUP STATEMENT OF FUNDS – PRIOR YEAR

	Balance at 1 October 2018 £	Income £	Expenditure £	Transfers In / out £	Gains / (Losses) £	Balance at 30 September 2019 £
Unrestricted and total funds						
Other General funds	6,209,664	1,796,255	(3,823,240)	-	93,325	4,276,004
Restricted funds						
Other restricted funds	100	4,000	(541)	-	-	3,559
Total of funds	6,209,764	1,800,255	(3,823,781)	-	93,325	4,279,563

The restricted funds received during the year of £4,000 was a grant from Groundwork UK, restricted to use specifically for lab coat learning.

NORTH WEST CANCER RESEARCH (INCORPORATING CLATTERBRIDGE CANCER RESEARCH “CCR”)

(A company limited by guarantee)

17. STATEMENT OF FUNDS continued

CHARITY STATEMENT OF FUNDS – CURRENT YEAR

	Balance at 1 October			Transfers	Gains /	Balance at 30 September
	2019	Income	Expenditure	In / out	(Losses)	2020
	£	£	£	£	£	£
Unrestricted and total funds						
Other General funds	4,079,099	1,534,969	(2,162,101)	-	(225,727)	3,226,241
Restricted funds						
Other restricted funds	3,559	3,000	(3,225)	-	-	3,334
Total of funds	4,082,658	1,537,969	(2,165,326)	-	(225,727)	3,229,575

CHARITY STATEMENT OF FUNDS – PRIOR YEAR

	Balance at 1 October			Transfers	Gains /	Balance at 30 September
	2018	Income	Expenditure	In / out	(Losses)	2019
	£	£	£	£	£	£
Unrestricted and total funds						
Other General funds	6,066,033	1,723,570	(3,796,745)	-	86,241	4,079,099
Restricted funds						
Other restricted funds	100	4,000	(541)	-	-	3,559
Total of funds	6,066,133	1,727,570	(3,797,286)	-	86,241	4,082,658

NORTH WEST CANCER RESEARCH (INCORPORATING CLATTERBRIDGE CANCER RESEARCH "CCR")

(A company limited by guarantee)

18. ANALYSIS OF NET ASSETS BETWEEN FUNDS

ANALYSIS OF NET ASSETS BETWEEN FUNDS – CURRENT YEAR

GROUP	Unrestricted and total funds 2020 £	Restricted funds 2020 £	Total funds 2020 £
Tangible fixed assets	5,917	-	5,917
Fixed asset investments	9,423,465	-	9,423,465
Current assets	1,420,753	3,334	1,424,086
Creditors due within one year	(4,934,713)	-	(4,934,713)
Creditors due in more than one year	(2,507,833)	-	(2,507,833)
	<u>3,407,588</u>	<u>3,334</u>	<u>3,410,922</u>

ANALYSIS OF NET ASSETS BETWEEN FUNDS – PRIOR YEAR

GROUP	<i>Unrestricted and total funds 2019 £</i>	<i>Restricted funds 2019 £</i>	<i>Total funds 2019 £</i>
Tangible fixed assets	7,568	-	7,568
Fixed asset investments	10,132,177	-	10,132,177
Current assets	978,469	3,559	982,028
Creditors due within one year	(3,484,226)	-	(3,484,226)
Creditors due in more than one year	(3,357,985)	-	(3,357,985)
	<u>4,276,004</u>	<u>3,559</u>	<u>4,279,563</u>

NORTH WEST CANCER RESEARCH (INCORPORATING CLATTERBRIDGE CANCER RESEARCH "CCR")

(A company limited by guarantee)

19. RECONCILIATION OF NET MOVEMENT IN FUNDS TO NET CASH FLOW FROM OPERATING ACTIVITIES

	2020 £	2019 £
Net expenditure for the year (as per Statement of Financial Activities)	(868,640)	(1,930,201)
Adjustment for:		
Depreciation charges	1,651	688
(Gains)/Losses on investments	234,701	(93,325)
Dividends, interest and rents from investments	(211,551)	(410,955)
Assets acquired	-	-
Increase in stocks	(6,984)	(2,902)
Increase in debtors	(3,038)	(272,378)
Increase/(decrease) in creditors	601,716	1,086,225
Net cash used in operating activities	(252,145)	(1,622,848)

20. ANALYSIS OF CASH AND CASH EQUIVALENTS

	2020 £	2019 £
Cash in hand	727,250	295,214
Investment cash accounts	523,667	347,219
	1,250,917	642,433

21. RECONCILIATION OF NET DEBT

	At 1 October 2019 £	Cashflow £	At 30 September 2020 £
Cash in hand and at bank	642,433	608,484	1,250,917
	642,433	608,484	1,250,917

NORTH WEST CANCER RESEARCH (INCORPORATING CLATTERBRIDGE CANCER RESEARCH "CCR")

(A company limited by guarantee)

22. PENSION COMMITMENTS

The Company contributes to personal pension plans. The assets of those plans are held separately from those of the Company in independently administered funds. Contributions totalling £3,601 (2019: £2,910) were payable to the plans at the balance sheet date and are included in creditors.

23. OPERATING LEASE COMMITMENTS

At 30 September 2020 the total of the Group's future minimum lease payments under non-cancellable operating leases was:

	2020 £	2019 £
Amounts payable:		
Within 1 year	1,368	1,368
Between 1 and 5 years	1,368	2,736
	<u>2,736</u>	<u>4,104</u>

Operating lease payments recognised during the year as an expense totalled £1,368 (2019: £1,416).

24. RELATED PARTY TRANSACTIONS

There are two related party transactions of note:

- At the period end £1 is owed to Clatterbridge Cancer Research Limited, the subsidiary company.
- A member of the Board of Trustees, Stephen Claus, is also a Partner of Brabners, the solicitors used by the Charity for many years. During the year the Charity used Brabners for legal services and advice on legacies and constitutional matters. The Charity was invoiced and paid £8,129 for these services. There was no payment for Trustee services.